Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors
Authors:
Open Access
- 22 July 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Pancreatology
- Vol. 2 (3) , 91-99
Abstract
The incidence rate of pancreatic neuroendocrine tumors (panNET) is increasing continuously. Curative resection was the primary treatment choice for panNET. However, till now, there were few studies concerning neo-adjuvant/conversion and adjuvant therapy for panNET. In this article, we reviewed the currently widely used medical treatments for advanced panNET. It seemed that peptide receptor radionuclide therapy (PRRT), chemotherapy (temozolomide-based or streptozocin-based) and sunitinib might be more effective to induce tumor shrinkage in panNET and therefore, these treatments could be tried in panNET when neo-adjuvant/conversion therapy was considered. As for adjuvant therapy, it was of great importance to identify patients with high risks of recurrence after curative surgery and previous studies found that high ki-67 index, large tumor size, lymphatic metastasis and perineural/vascular invasion, and so on, were correlated with early recurrence of panNET. Since PRRT and chemotherapy were more cytotoxic, these two kinds of therapies might be worth trying as adjuvant therapies in patients with high risks of recurrence after curative resection of panNET. Admittedly, no studies discussed in this review directly investigated neo-adjuvant/conversion and adjuvant therapy for panNET. Therefore, more prospective studies were still warranted.Keywords
This publication has 102 references indexed in Scilit:
- Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumorInvestigational New Drugs, 2013
- DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 2011
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursBritish Journal of Cancer, 2010
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR PathwayJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Activity of Sunitinib in Patients With Advanced Neuroendocrine TumorsJournal of Clinical Oncology, 2008
- Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine TumorsClinical Cancer Research, 2007
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986